Swiss National Bank - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.

Quarter-by-quarter ownership
Swiss National Bank ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$1,444,266
+71.8%
77,900
+2.5%
0.00%0.0%
Q2 2023$840,560
-17.6%
76,0000.0%0.00%0.0%
Q1 2023$1,020,680
+2.8%
76,000
-5.4%
0.00%0.0%
Q4 2022$993,311
+28.0%
80,300
+44.4%
0.00%0.0%
Q3 2022$776,000
+1.0%
55,6000.0%0.00%0.0%
Q2 2022$768,000
-20.5%
55,600
-6.4%
0.00%0.0%
Q1 2022$966,000
-4.2%
59,400
-4.0%
0.00%0.0%
Q4 2021$1,008,000
+9.7%
61,9000.0%0.00%0.0%
Q3 2021$919,000
-25.6%
61,9000.0%0.00%0.0%
Q2 2021$1,236,000
-10.3%
61,900
+3.7%
0.00%0.0%
Q1 2021$1,378,000
-6.6%
59,7000.0%0.00%0.0%
Q4 2020$1,475,000
-40.4%
59,7000.0%0.00%
-50.0%
Q3 2020$2,475,000
-12.0%
59,700
+1.7%
0.00%0.0%
Q2 2020$2,812,000
-12.1%
58,700
+15.6%
0.00%
-33.3%
Q1 2020$3,198,000
-48.5%
50,800
+1.4%
0.00%
-50.0%
Q4 2019$6,208,000
+93.3%
50,100
+3.5%
0.01%
+100.0%
Q3 2019$3,212,000
-8.5%
48,400
+9.8%
0.00%
-25.0%
Q2 2019$3,509,000
-17.2%
44,100
+16.4%
0.00%
-20.0%
Q1 2019$4,239,000
+14.9%
37,900
+3.6%
0.01%0.0%
Q4 2018$3,689,000
-19.1%
36,600
+1.4%
0.01%0.0%
Q3 2018$4,562,000
+54.0%
36,100
+2.3%
0.01%
+66.7%
Q2 2018$2,962,000
+57.9%
35,300
+15.7%
0.00%
+50.0%
Q1 2018$1,876,000
+10.0%
30,500
+4.5%
0.00%0.0%
Q4 2017$1,706,000
+0.6%
29,2000.0%0.00%0.0%
Q3 2017$1,695,000
-52.1%
29,2000.0%0.00%
-50.0%
Q2 2017$3,535,000
+9.7%
29,200
+2.5%
0.00%0.0%
Q1 2017$3,223,000
+6.3%
28,500
+2.2%
0.00%
-20.0%
Q4 2016$3,031,000
-34.0%
27,9000.0%0.01%
-28.6%
Q3 2016$4,592,000
+14.9%
27,900
-0.4%
0.01%
+16.7%
Q2 2016$3,995,000
+15.1%
28,0000.0%0.01%0.0%
Q1 2016$3,471,000
+5.1%
28,000
+26.7%
0.01%
-25.0%
Q4 2015$3,301,000
-10.0%
22,1000.0%0.01%
-11.1%
Q3 2015$3,666,000
-20.5%
22,100
+15.7%
0.01%
-25.0%
Q2 2015$4,610,000
-9.2%
19,100
+6.1%
0.01%
-14.3%
Q1 2015$5,076,000
+112.7%
18,000
+17.6%
0.01%
+55.6%
Q4 2014$2,387,000
-32.3%
15,300
+2.7%
0.01%
-35.7%
Q3 2014$3,527,000
+1.4%
14,900
+1.4%
0.01%
+7.7%
Q2 2014$3,478,00014,7000.01%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders